Asset Details
Do you wish to reserve the book?
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
Do you wish to request the book?
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine
2011
Overview
There is a need for a rapid-acting, non-injection, acute treatment for agitation.
To evaluate inhaled loxapine for acute treatment of agitation in schizophrenia.
This phase III, randomised, double-blind, placebo-controlled, parallel-group study (ClinicalTrials.gov number NCT00628589) enrolled 344 individuals who received one, two or three doses of inhaled loxapine (5 or 10 mg) or a placebo. Lorazepam rescue was permitted after dose two. The primary efficacy end-point was change from baseline in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) 2 h after dose one. The key secondary end-point was Clinical Global Impression-Improvement scale (CGI-I) score 2 h after dose one.
Inhaled loxapine (5 and 10 mg) significantly reduced agitation compared with placebo as assessed by primary and key secondary end-points. Reduced PANSS-EC score was evident 10 min after dose one with both 5 and 10 mg doses. Inhaled loxapine was well tolerated, and the most common adverse events were known effects of loxapine or minor oral effects common with inhaled medications.
Inhaled loxapine provided a rapid, well-tolerated acute treatment for agitation in people with schizophrenia.
Publisher
Cambridge University Press
Subject
/ Adult
/ Aerosols
/ Aged
/ Antipsychotic Agents - administration & dosage
/ Antipsychotic Agents - adverse effects
/ Dosage
/ Dose-Response Relationship, Drug
/ Drugs
/ Efficacy
/ Female
/ Humans
/ Loxapine - administration & dosage
/ Male
/ Patients
/ Placebos
/ Psychiatric Status Rating Scales
/ Psychomotor Agitation - drug therapy
